Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

957 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Isolation of human monoclonal antibodies with neutralizing activity to a broad spectrum of SARS-CoV-2 viruses including the Omicron variants.
Ueno M, Iwata-Yoshikawa N, Matsunaga A, Okamura T, Saito S, Ashida S, Yoshida I, Nagashima M, Asakura H, Yaoita Y, Suzuki J, Sadamasu K, Yoshimura K, Kutsuna S, Shiwa-Sudo N, Nagata N, Suzuki T, Suzuki A, Okamoto M, Kimura M, Ohmagari N, Miura R, Ishizaka Y. Ueno M, et al. Among authors: nagashima m. Antiviral Res. 2022 May;201:105297. doi: 10.1016/j.antiviral.2022.105297. Epub 2022 Mar 24. Antiviral Res. 2022. PMID: 35341809 Free PMC article.
Drug-resistant HIV-1 prevalence in patients newly diagnosed with HIV/AIDS in Japan.
Gatanaga H, Ibe S, Matsuda M, Yoshida S, Asagi T, Kondo M, Sadamasu K, Tsukada H, Masakane A, Mori H, Takata N, Minami R, Tateyama M, Koike T, Itoh T, Imai M, Nagashima M, Gejyo F, Ueda M, Hamaguchi M, Kojima Y, Shirasaka T, Kimura A, Yamamoto M, Fujita J, Oka S, Sugiura W. Gatanaga H, et al. Among authors: nagashima m. Antiviral Res. 2007 Jul;75(1):75-82. doi: 10.1016/j.antiviral.2006.11.012. Epub 2006 Dec 14. Antiviral Res. 2007. PMID: 17194486
Trends in transmitted drug-resistant HIV-1 and demographic characteristics of newly diagnosed patients: nationwide surveillance from 2003 to 2008 in Japan.
Hattori J, Shiino T, Gatanaga H, Yoshida S, Watanabe D, Minami R, Sadamasu K, Kondo M, Mori H, Ueda M, Tateyama M, Ueda A, Kato S, Ito T, Oie M, Takata N, Hayashida T, Nagashima M, Matsuda M, Ibe S, Ota Y, Sasaki S, Ishigatsubo Y, Tanabe Y, Koga I, Kojima Y, Yamamoto M, Fujita J, Yokomaku Y, Koike T, Shirasaka T, Oka S, Sugiura W. Hattori J, et al. Among authors: nagashima m. Antiviral Res. 2010 Oct;88(1):72-9. doi: 10.1016/j.antiviral.2010.07.008. Epub 2010 Aug 6. Antiviral Res. 2010. PMID: 20692295
Characteristics of SARS-CoV-2 Isolated from Asymptomatic Carriers in Tokyo.
Nagashima M, Kumagai R, Yoshida I, Kawakami M, Nagano M, Asakura H, Kaku E, Kitamura Y, Hasegawa M, Hayashi Y, Chiba T, Sadamasu K, Yoshimura K. Nagashima M, et al. Jpn J Infect Dis. 2020 Jul 22;73(4):320-322. doi: 10.7883/yoken.JJID.2020.137. Epub 2020 Apr 30. Jpn J Infect Dis. 2020. PMID: 32350227 Free article. No abstract available.
Cautious handling of urine from moderate to severe COVID-19 patients.
Nomoto H, Ishikane M, Katagiri D, Kinoshita N, Nagashima M, Sadamasu K, Yoshimura K, Ohmagari N. Nomoto H, et al. Among authors: nagashima m. Am J Infect Control. 2020 Aug;48(8):969-971. doi: 10.1016/j.ajic.2020.05.034. Epub 2020 Jun 2. Am J Infect Control. 2020. PMID: 32502614 Free PMC article. No abstract available.
Does the SARS-CoV-2 rapid antigen test result correlate with the viral culture result?
Yamamoto K, Nagashima M, Yoshida I, Sadamasu K, Kurokawa M, Nagashima M, Kinoshita N, Maeda K, Takasaki J, Teruya K, Ohmagari N. Yamamoto K, et al. Among authors: nagashima m. J Infect Chemother. 2021 Aug;27(8):1273-1275. doi: 10.1016/j.jiac.2021.05.006. Epub 2021 May 12. J Infect Chemother. 2021. PMID: 34023222 Free PMC article.
957 results